Nanobiotix (NBTX) Competitors $19.20 -0.08 (-0.41%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$19.26 +0.07 (+0.34%) As of 10/24/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NBTX vs. AKRO, CRNX, MENS, NAMS, KYMR, SRRK, VKTX, MIRM, LNTH, and ADMAShould you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include Akero Therapeutics (AKRO), Crinetics Pharmaceuticals (CRNX), Jyong Biotech (MENS), NewAmsterdam Pharma (NAMS), Kymera Therapeutics (KYMR), Scholar Rock (SRRK), Viking Therapeutics (VKTX), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Nanobiotix vs. Its Competitors Akero Therapeutics Crinetics Pharmaceuticals Jyong Biotech NewAmsterdam Pharma Kymera Therapeutics Scholar Rock Viking Therapeutics Mirum Pharmaceuticals Lantheus ADMA Biologics Nanobiotix (NASDAQ:NBTX) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends. Is NBTX or AKRO more profitable? Nanobiotix's return on equity of 0.00% beat Akero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NanobiotixN/A N/A N/A Akero Therapeutics N/A -15.84%-14.59% Which has more volatility & risk, NBTX or AKRO? Nanobiotix has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.29, indicating that its stock price is 129% less volatile than the S&P 500. Do analysts recommend NBTX or AKRO? Nanobiotix presently has a consensus target price of $11.00, suggesting a potential downside of 42.71%. Akero Therapeutics has a consensus target price of $73.38, suggesting a potential upside of 36.46%. Given Akero Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akero Therapeutics is more favorable than Nanobiotix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanobiotix 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Akero Therapeutics 1 Sell rating(s) 7 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.31 Does the media favor NBTX or AKRO? In the previous week, Akero Therapeutics had 1 more articles in the media than Nanobiotix. MarketBeat recorded 8 mentions for Akero Therapeutics and 7 mentions for Nanobiotix. Akero Therapeutics' average media sentiment score of 1.11 beat Nanobiotix's score of 0.65 indicating that Akero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 1 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Akero Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of NBTX or AKRO? 38.8% of Nanobiotix shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 7.1% of Akero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation & earnings, NBTX or AKRO? Nanobiotix has higher revenue and earnings than Akero Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNanobiotix$39.18M23.49-$73.73MN/AN/AAkero TherapeuticsN/AN/A-$252.06M-$2.00-26.89 SummaryNanobiotix and Akero Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBTX vs. The Competition Export to ExcelMetricNanobiotixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$920.51M$2.63B$6.22B$10.81BDividend YieldN/A57.77%5.72%4.81%P/E RatioN/A27.9431.5030.91Price / Sales23.49786.96594.92133.93Price / CashN/A168.8137.2561.86Price / Book-12.725.6512.056.61Net Income-$73.73M$33.06M$3.34B$277.10M7 Day Performance-25.00%3.16%1.93%2.57%1 Month Performance30.17%8.14%7.77%3.79%1 Year Performance325.72%-2.49%56.40%33.01% Nanobiotix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBTXNanobiotix0.6535 of 5 stars$19.20-0.4%$11.00-42.7%+304.2%$920.51M$39.18M0.00100News CoverageAnalyst UpgradeAKROAkero Therapeutics3.8001 of 5 stars$53.66-0.4%$73.38+36.7%+87.0%$4.31BN/A-26.8330Positive NewsAnalyst ForecastCRNXCrinetics Pharmaceuticals4.1959 of 5 stars$44.43-1.1%$74.45+67.6%-30.2%$4.23B$1.04M-10.81210Positive NewsAnalyst ForecastMENSJyong BiotechN/A$55.70+0.8%N/AN/A$4.20BN/A0.0031Positive NewsAnalyst ForecastGap UpNAMSNewAmsterdam Pharma3.3938 of 5 stars$37.15+0.3%$42.00+13.1%+89.4%$4.17B$45.56M-22.934Analyst ForecastAnalyst RevisionHigh Trading VolumeKYMRKymera Therapeutics1.374 of 5 stars$59.89+4.7%$61.26+2.3%+20.2%$4.09B$47.07M-17.26170News CoverageUpcoming EarningsAnalyst ForecastSRRKScholar Rock4.4658 of 5 stars$34.28-13.1%$48.60+41.8%+2.3%$3.79B$33.19M-11.78140Analyst ForecastHigh Trading VolumeVKTXViking Therapeutics4.06 of 5 stars$33.91+1.0%$86.42+154.8%-53.0%$3.77BN/A-22.1620Trending NewsEarnings ReportAnalyst DowngradeAnalyst RevisionGap UpMIRMMirum Pharmaceuticals3.7368 of 5 stars$72.17-0.7%$76.50+6.0%+77.9%$3.65B$336.89M-59.64140Analyst ForecastLNTHLantheus4.596 of 5 stars$54.59+2.0%$74.50+36.5%-48.9%$3.64B$1.53B14.52700Trending NewsAnalyst DowngradeADMAADMA Biologics3.5796 of 5 stars$14.55+0.1%$27.67+90.1%-4.9%$3.47B$426.45M16.92530News CoverageAnalyst Downgrade Related Companies and Tools Related Companies Akero Therapeutics Competitors Crinetics Pharmaceuticals Competitors Jyong Biotech Competitors NewAmsterdam Pharma Competitors Kymera Therapeutics Competitors Scholar Rock Competitors Viking Therapeutics Competitors Mirum Pharmaceuticals Competitors Lantheus Competitors ADMA Biologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBTX) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NBTX Stock Alerts